Brain metastases are a common source of morbidity for patients with cancer, and limited data exist to support the local therapeutic choice between surgical resection and stereotactic radiosurgery (SRS).
B rain metastases are a common source of cancer morbidity, accounting for approximately 140 000 cases annually in the United States.
1 Local therapies, including stereotactic radiosurgery (SRS) and surgical resection, result in improved survival relative to whole-brain radiotherapy (WBRT) alone among patients with a single lesion. 2, 3 Outside recognized indications for surgery such as establishing diagnosis or relieving mass effect, little evidence is available to guide the therapeutic choice of SRS vs surgical resection in the treatment of patients with limited brain metastases. The European Organization for the Research and Treatment of Cancer (EORTC) 22952-26001 phase 3 trial assessed the role of adjuvant WBRT after local therapy (SRS or surgical resection) in patients with 1 to 3 brain metastases. 4 In the original trial, patients were stratified by SRS or surgical resection and had surveillance with neuroimaging while receiving per protocol treatment. The purpose of our study was to assess local control of treated brain metastases among patients in EORTC 22952-26001 by SRS vs surgical resection.
Methods

Study Design
We performed an unplanned, exploratory analysis of EORTC 22952-26001 data. We included patients treated per protocol with 1 to 2 brain metastases and tumor diameter of no greater than 4 cm. The original trial allocated patients with 1 to 3 brain metastases to WBRT vs observation after surgical resection or before SRS. Patients were stratified but not randomized according to SRS or surgical resection. Follow-up examinations, including imaging of the brain, were performed 8 weeks after SRS or surgical resection and every 3 months thereafter. Data were collected from February 9, 2017, through July 25, 2018. This study was approved by the local institutional ethics committees, and all patients provided written informed consent.
Statistical Analysis
We defined the primary end point as local recurrence of treated brain metastases; the protocol specified local neurologic progression as an increase on magnetic resonance imaging of more than 25% of the size (in the 2 largest perpendicular diameters) of 1 of the original brain metastases. We compared categorical variables using the χ 2 test or Fisher exact test and continuous variables using unpaired 2-sample, 2-sided t tests. We calculated cumulative incidence of local recurrence according to local therapy (SRS vs surgical resection) and compared incidence between groups using the Gray test to account for competing risk of all-cause mortality. For reference, we calculated the cumulative incidences of distant neurologic progression and all-cause mortality. In adjusted models stratified by WBRT, we used competing risk regression to adjust for covariates and account for competing risk of allcause mortality. Covariates included diameter of largest brain metastasis, neurologic status, metastasis site, presence of macroscopic tumor outside the brain, and number of brain metastases. We tested for violations of the proportional hazards assumption by adding an effect of log-time to the Fine and Gray multiple regression model, which demonstrated substantial violations of proportionality. For ease of interpretation, we allowed the hazard ratios (HRs) to vary in discrete intervals early in the study; we chose intervals of 0 to 3, 3 to 6, 6 to 9, and greater than 9 months based on the period when hazards changed most substantially and because including these intervals resulted in nonsignificance of the test for violations of proportionality. We defined time of randomization as time 0. We performed a sensitivity analysis defining time 0 as completion of local therapy, because patients were randomized after surgical resection and before SRS. We performed statistical analysis with SAS software (version 9.4; SAS Institute, Inc), considered α<.05 for statistical significance, and reported 2-sided P values.
Results
We Table 1) . Unadjusted cumulative incidence of local recurrence was significantly higher among patients with surgical resection; however, local recurrence was similar between the SRS and surgical resection groups receiving WBRT ( Findings In this exploratory analysis of the European Organization for the Research and Treatment of Cancer 22952-26001 trial including 268 patients with brain metastases, those undergoing stereotactic radiosurgery exhibited similar local tumor control to patients undergoing surgical resection after adjustment for tumor size, neurologic status, metastasis site, number of metastases, and presence of extracranial disease. However, risk of early local recurrence was higher among patients undergoing surgery, whereas risk of late recurrence was higher among those undergoing stereotactic radiosurgery.
Meaning Surgical resection and stereotactic radiosurgery achieve comparable local control of brain metastases; future study should identify whether any patients benefit from escalations in local therapy.
1). The adjusted risk of local brain metastasis recurrence is outlined in Table 2 . Adjusted risk of local recurrence was similar after surgical resection and SRS (HR, 1.15; 95% CI, 0.72-1.83). However, the risk of local recurrence by modality varied according to time (P < .001 for interaction); early recurrence was associated with surgical resection (HR at 0-3 months, 5.94; 95% CI, 1.72-20.45), whereas late recurrence was associated with SRS (HR at >9 months, 2.77; 95% CI, 1.08-7.12). In adjusted models, increasing tumor size was associated with increased risk of local recurrence (HR, 1.03; 95% CI, 1.00-1.06), whereas the presence of macroscopic tumor outside the brain was associated with decreased risk of local recurrence (HR, 0.63; 95% CI, 0.40-0.99). Cumula- 
Discussion
The principal finding of our exploratory analysis of EORTC 22952-26001 is similar overall local control of brain metastases treated with SRS compared with surgical resection after adjustment for tumor size, metastasis site and number, neurologic status, and the presence of extracranial disease. Early local control favored SRS, although the advantage diminished in magnitude over time with more late recurrences observed in the SRS group. Our findings are comparable to those of a randomized clinical trial demonstrating no significant differences in local control at 1 year between surgical resection and WBRT (82%) vs SRS (96.8%; P = .06).
5 This trial was limited in power, accruing only 64 of 242 planned patients. In contrast, an institutional series of 75 patients with brain metastasis 6 reported superior local control and overall survival after surgical resection compared with matched-paired patients receiving SRS. Another institutional series of patients with brain metastases from melanoma 7 found improved local control for postoperative SRS compared with SRS alone. In unadjusted analyses, local recurrence approached 50% by 9 months after surgical resection without adjuvant WBRT. Postoperative cavity SRS has been investigated as a means to redress poor local control after surgical resection in the absence of WBRT. [8] [9] [10] Alliance N107C compared postoperative SRS with WBRT after surgical resection; overall survival was comparable and cognitive-deterioration-free survival was supe- 
Limitations
Limitations of our study arise from post hoc analysis. Although tumor size was accounted for in adjusted models, those treated with surgery had larger median tumor sizes, and increasing tumor size was associated with local recurrence. Other unmeasured confounders are likely derived from patient selection for local therapy outside of our adjusted models. Matching was not feasible due to the small sample size. The strength of this analysis lies within the high-quality data abstracted from an international phase 3 trial with scheduled brain surveillance. Incidence is stratified according to local therapy and receipt of whole-brain radiotherapy (WBRT). SRS indicates stereotactic radiosurgery.
Conclusions
Our exploratory analysis of the EORTC 22952-26001 trial found similar local control of treated brain metastases with SRS compared with surgical resection. Although early local control was improved in the SRS group, the risk of local recurrence increased with time for SRS relative to surgical resection. Prospective controlled trials are warranted to direct the optimal local approach for patients with brain metastases and to define whether any population may benefit from escalation in local therapy.
eFigure 1. CONSORT Diagram for Patient Selection
We excluded patients with three brain metastases as they were treated exclusively with SRS and patients with tumor sizes > 4 cm as they were treated exclusively with surgical resection.
Abbreviations: SRS = Stereotactic radiosurgery, WBRT = Whole brain radiotherapy. 
